샘플 요청 목록

 카트 문의
시장보고서
상품코드
1776204

신장 이식 치료제 시장 : 시장 인사이트, 경쟁 구도, 시장 예측(2032년)

Renal Transplant Therapeutics - Market Insights, Competitive Landscape, and Market Forecast - 2032
발행일: | 리서치사: DelveInsight | 페이지 정보: 영문 150 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

전 세계 신장 이식 치료제 시장 규모는 2024년 113억 5,970만 달러로 2032년까지 183억 9,830만 달러에 달할 것으로 예상되며, 2025-2032년 예측 기간 동안 6.29%의 CAGR로 성장할 것으로 예상됩니다. 신장 이식 치료제의 수요는 여러 요인에 의해 촉진되고 있습니다. 만성 신장 질환(CKD), 신부전, 말기 신부전(ESRD)의 유병률이 증가함에 따라 전 세계적으로 신장 이식 건수가 증가하고 있습니다. 이러한 질환은 종종 영구적인 신장 기능 장애로 이어지기 때문에 이식에 대한 수요가 증가하고 있습니다. 또한, 연구개발 활동의 활성화와 이식 거부반응을 예방하기 위한 신제품의 도입도 시장 성장에 크게 기여하고 있습니다. 주요 제약사들의 치료 제품 혁신과 확대 노력은 신장 이식 치료제 시장에 유리한 환경을 조성하고 있습니다. 이러한 추세로 인해 2025-2032년 동안 신장 이식 치료제 시장은 건강하고 꾸준한 성장을 보일 것으로 예상됩니다.

신장 이식 치료제 시장 역학

World Health Organization Global Observatory on Donation and Transplantation(2024)의 데이터에 따르면, 2023년 전 세계에서 신장, 간, 심장 등 장기 이식이 약 17만 2,409건 이루어졌습니다. 신장 이식이 11만 1,135건으로 대부분을 차지했으며, 이는 2022년 전 세계 신장 이식 건수 10만 2,090건에서 9% 증가한 수치로, GODT 데이터에 따르면 2023년 신장 이식 중 4만 3,101건은 생체 기증자, 6만 8,034건은 사망자 기증자에 의한 것이었습니다. 이러한 이식 수술의 증가 추세는 장기 거부반응을 예방하고 이식편의 장기 생존을 보장하는 데 중요한 효과적인 이식 후 관리의 필요성이 전 세계적으로 증가하고 있음을 보여줍니다.

이식 후 관리의 핵심은 일반적으로 항거부반응제라고 불리는 면역억제제의 사용입니다. 이 치료제는 이식된 신장을 이물질로 인식하는 면역계의 자연적인 반응을 억제함으로써 신장 이식의 성공에 중요한 역할을 합니다. 면역억제제가 없으면 이러한 면역반응이 이식편 손상이나 완전한 거부반응으로 이어질 수 있습니다. 일반적으로 이러한 약물은 급성 거부반응과 만성 거부반응의 위험을 줄이기 위해 장기간에 걸쳐 투여됩니다.

일부 국가에서는 신장 이식 건수가 증가하고 있습니다. 예를 들어, Kidney Care UK(2022)의 자료에 따르면 영국에서는 연간 약 3,600건의 신장 이식이 이루어지고 있으며, 약 5,000명이 대기자 명단에 남아 있는 것으로 보고되고 있습니다. 마찬가지로 호주에서는 Australian Institute of Health and Welfare(2024)에 따르면 2022년에 938건의 신장 이식이 이루어졌으며, 그 중 90%가 첫 번째 이식이었다고 보고했습니다. 이 중 713건(76%)은 사망한 기증자로부터, 225건(24%)은 살아있는 기증자로부터의 이식입니다. 전 세계적으로 신장이식 수술이 증가함에 따라 포괄적이고 장기적인 신장이식 치료에 대한 수요도 함께 증가하고 있습니다. 여기에는 면역억제제 및 항감염제뿐만 아니라 이식 결과를 개선하기 위한 기술 혁신도 포함됩니다.

또한, 제품 개발 및 규제 당국의 승인은 이식 치료제 시장의 성장을 촉진하고 있습니다. 예를 들어, 2024년 3월, 신장 질환 치료에 특화된 임상 단계의 생명공학 기업 Unicycive Therapeutics, Inc.는 미국 식품의약국(FDA)이 UNI-494에 희귀질환 치료제 지정(ODD)을 부여했다고 발표했습니다. 이 임상시험용 의약품은 신장 이식 후 심각한 합병증인 이식편 기능 지연(DGF)을 예방하는 것을 목표로 하고 있습니다.

그러나 신장 이식 치료제와 관련된 장기적인 위험과 잠재적인 부작용, 의약품 승인에 대한 엄격한 규제 요건 등은 신장 이식 치료제 시장의 성장을 제한할 수 있는 중요한 억제요인으로 작용하고 있습니다.

북미가 전체 신장 이식 치료제 시장을 독식할 것으로 예상

여러 요인으로 인해 북미는 2024년 신장 이식 치료제 시장에서 가장 큰 점유율을 차지할 것으로 예상됩니다. 이 지역의 우위는 CKD 및 ESRD와 같은 신장 질환의 유병률 증가, 신장 이식 건수 증가, 잘 구축된 의료 인프라, 주요 기업의 지속적인 제품 개발 등이 주요 요인으로 작용하고 있습니다. 이러한 요인들로 인해 북미는 세계 신장이식 치료제 시장에서 주도적인 위치를 차지하고 있습니다.

세계의 신장 이식 치료제 시장에 대해 조사 분석했으며, 시장 규모와 예측, 최근 3년간의 제품/기술 개발, 주요 기업, 시장 기회 등의 정보를 전해드립니다.

목차

제1장 신장 이식 치료제 시장 보고서 소개

제2장 신장 이식 치료제 시장 주요 요약

  • 시장 개요

제3장 경쟁 구도

제4장 규제 분석

  • 미국
  • 유럽
  • 일본
  • 중국

제5장 신장 이식 치료제 시장의 주요 요인 분석

  • 신장 이식 치료제 시장 촉진요인
  • 신장 이식 치료제 시장 억제요인과 과제
  • 신장 이식 치료제 시장 기회

제6장 신장 이식 치료제 시장 Porter's Five Forces 분석

제7장 신장 이식 치료제 시장 평가

  • 약물 종류별
    • 칼시뉴린 억제제
    • 인터류킨 억제제
    • mTOR 억제제
    • 이노신 일인산 탈수소효소(IMPDH) 억제제
    • 기타
  • 투여 경로
    • 경구
    • 비경구
  • 모달리티별
    • 소분자
    • 생물학적 제제
  • 지역
    • 북미
    • 유럽
    • 아시아태평양
    • 기타 지역

제8장 신장 이식 치료제 시장 기업과 제품 개요

  • Novartis AG
  • Sanofi
  • Astellas Pharma Inc.
  • Asahi Kasei Corporation
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • GSK plc
  • Biogen
  • Zydus Group
  • Eledon Pharmaceuticals, Inc.
  • AbbVie Inc.
  • CSL
  • Teva Pharmaceutical Industries Ltd.
  • Johnson & Johnson Services, Inc.

제9장 KOL의 견해

제10장 프로젝트 접근법

제11장 DelveInsight 소개

제12장 면책사항, 문의

ksm 25.07.30

Renal Transplant Therapeutics Market by Drug Class (Calcineurin Inhibitors, Interleukin Inhibitors, mTOR Inhibitors, IMPDH Inhibitors, and Others), Route of Administration (Oral and Parenteral), Modality (Small Molecule and Biologics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing number of kidney transplant performed globally and the rising prevalence of chronic kidney disease, renal failure, end-stage renal disease (ESRD) and its associated risk factors.

The renal transplant therapeutics market was valued at USD 11,359.70 million in 2024, growing at a CAGR of 6.29% during the forecast period from 2025 to 2032 to reach USD 18,398.30 million by 2032. The demand for renal transplant therapeutics is being driven by several key factors. Foremost among these is the growing number of kidney transplants performed globally, alongside the rising prevalence of chronic kidney disease (CKD), renal failure, and end-stage renal disease (ESRD). These conditions often lead to permanent damage to kidney function, thereby increasing the need for transplantation. In addition, a surge in research and development activities, along with the introduction of new products aimed at preventing transplant rejection, is contributing significantly to market growth. The efforts by leading pharmaceutical companies to innovate and expand their therapeutic offerings are creating a favorable environment for the renal transplant therapeutics market. Together, these trends are positioning the market for robust and steady expansion from 2025 to 2032.

Renal Transplant Therapeutics Market Dynamics:

According to the data provided by the World Health Organization Global Observatory on Donation and Transplantation (2024), in 2023, approximately 172,409 organ transplants were performed worldwide, including kidney, liver, heart, and other organs. Kidney transplants accounted for the majority, with 111,135 procedures, a notable 9% increase from the 102,090 kidney transplants conducted globally in 2022. Of the kidney transplants performed in 2023, GODT data revealed that 43,101 were from living donors, while 68,034 were from deceased donors. This upward trend in transplant procedures highlights an increasing global need for effective post-transplant care, which is critical in preventing organ rejection and ensuring long-term graft survival.

A cornerstone of post-transplant management is the use of immunosuppressant medications, commonly referred to as anti-rejection drugs. These therapies play a vital role in kidney transplant success by suppressing the immune system's natural response to recognize the transplanted kidney as a foreign object. Without immunosuppressants, this immune reaction can lead to graft damage or complete rejection. Typically, these medications are administered long-term to reduce the risk of both acute and chronic rejection episodes.

The growing number of kidney transplants is also increasing in countries. For example, data from Kidney Care UK (2022) reported that approximately 3,600 kidney transplants were performed annually in the United Kingdom, while nearly 5,000 individuals remained on the waiting list. Similarly, in Australia, the Australian Institute of Health and Welfare (2024) reported 938 kidney transplants in 2022, with 90% being first-time transplants. Of these, 713 were from deceased donors (76%), and 225 from living donors (24%). The global rise in kidney transplant procedures is driving a parallel increase in demand for comprehensive and long-term renal transplant therapies. This includes not only immunosuppressants and anti-infective agents but also innovations aimed at improving transplant outcomes.

Moreover, product development and regulatory approvals are fostering growth in the transplant therapeutics market. For instance, in March 2024, Unicycive Therapeutics, Inc., a clinical-stage biotechnology company focused on kidney disease therapies, announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to UNI-494. This investigational therapy is aimed at preventing Delayed Graft Function (DGF), a serious complication following kidney transplantation.

However, the long-term risk and potential adverse effects associated with kidney transplant drugs and stringent regulatory requirements for drug approval, among others, are some of the key constraints that may limit the growth of the renal transplant therapeutics market.

Renal Transplant Therapeutics Market Segment Analysis:

Renal Transplant Therapeutics Market by Drug Class (Calcineurin Inhibitors, Interleukin Inhibitors, mTOR Inhibitors, IMPDH Inhibitors, and Others), Route of Administration (Oral and Parenteral), Modality (Small Molecule and Biologics), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the drug class segment of the renal transplant therapeutics market, the calcineurin inhibitors category is estimated to account for the largest market share in 2024. The growth of the calcineurin inhibitors category is being significantly driven by the rising global cases of kidney transplants and the critical clinical role of calcineurin inhibitors (CNIs) in preventing organ rejection. These agents are well-established, FDA-approved, and remain the cornerstone of immunosuppressive regimens in renal transplantation.

One of the key strengths of calcineurin inhibitors lies in their high efficacy in preventing acute rejection episodes. By targeting the calcineurin pathway, CNIs inhibit T-cell activation and suppress the production of interleukin-2 (IL-2), a cytokine essential for T-cell proliferation. This mechanism significantly lowers the risk of early acute rejection when compared to older immunosuppressive strategies. Beyond acute rejection prevention, CNIs have played a pivotal role in improving long-term graft survival. Their ability to suppress T-cell-mediated immune responses helps mitigate chronic graft injury, a major contributor to late transplant failure.

In clinical practice, CNIs are typically administered as part of a triple immunosuppressive regimen, often in combination with antimetabolites such as mycophenolate mofetil and corticosteroids. This multimodal approach allows physicians to balance efficacy and safety by using lower doses of each agent, thereby reducing drug-specific toxicities while maintaining robust immune suppression.

Among the most prominent calcineurin inhibitors are:

  • PROGRAF(R) (tacrolimus) by Astellas Pharma is indicated for the prevention of organ rejection in kidney transplant recipients. It is widely considered a first-line therapy due to its potent immunosuppressive profile.
  • NEORAL(R) (cyclosporine capsules, USP) by Novartis is a widely used calcineurin inhibitor, approved to reduce the risk of graft rejection, particularly in patients who may not tolerate tacrolimus or require tailored immunosuppressive management.

Thus, the factors mentioned above are likely to boost the market segment and thereby increase the overall market of renal transplant therapeutics across the globe.

North America is expected to dominate the overall renal transplant therapeutics market:

North America is projected to hold the largest share of the renal transplant therapeutics market in 2024, driven by several key factors. This regional dominance is primarily attributed to the rising prevalence of kidney diseases such as CKD and ESRD, a growing number of kidney transplants, a well-established healthcare infrastructure, and ongoing product development by leading companies. Collectively, these factors are positioning North America as the leading market in the global renal transplant therapeutics market.

According to the Centers for Disease Control and Prevention (CDC, 2024), in 2023, approximately 35.5 million U.S. adults, about 14% of the population, were living with CKD. Supporting this, the American Kidney Fund (2024) reported that around 808,000 individuals were living with kidney failure, with 135,000 new cases diagnosed in 2022, underscoring the escalating burden of kidney-related conditions in the country.

As per the data from the Kidney Foundation of Canada (2023, every 1 in 10 people, accounting for approximately 4 million people, were suffering from kidney disease in Canada. This growing burden of kidney disease in the region has led to increased transplant procedures, fueling the need for effective immunosuppressive and anti-infective therapies to support long-term graft survival, thereby driving the market growth.

As per the latest data from the Organ Procurement and Transplantation Network (OPTN, 2025), in 2023, over 27,759 kidney transplants were performed in the United States, while the National Kidney Foundation (2023) noted more than 25,000 kidney transplants in 2022 alone. These high transplant volumes are driving demand for renal transplant therapeutics, particularly immunosuppressants and infection-preventive therapies.

Furthermore, key industry players in the region are actively advancing transplant-related drug development. For example, in October 2024, Biogen announced that felzartamab, an investigational anti-CD38 monoclonal antibody, received Breakthrough Therapy Designation (BTD) from the U.S. FDA for treating late antibody-mediated rejection (AMR) in kidney transplant recipients, without concurrent T-cell-mediated rejection.

Therefore, the combination of a rising number of kidney transplant procedures, a high prevalence of kidney disease, and ongoing innovation in transplant therapeutics is expected to significantly propel the growth of the renal transplant therapeutics market in the North America from 2025 to 2032.

Renal Transplant Therapeutics Market Key Players:

Some of the key market players operating in the renal transplant therapeutics market include Novartis AG, Sanofi, Astellas Pharma Inc., Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd., Pfizer Inc., Bristol-Myers Squibb Company, GSK plc, Biogen, Zydus Group, Eledon Pharmaceuticals, Inc., AbbVie Inc., CSL, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., and others.

Recent Developmental Activities in the Renal Transplant Therapeutics Market:

  • In March 2025, Zydus announced the launch of ANVIMO (Letermovir), marking a significant advancement in the prevention of Cytomegalovirus (CMV) infection among kidney transplant recipients. ANVIMO offers a safer, well-tolerated, and effective alternative to existing therapies, with superior safety, fewer side effects, and the potential to enhance post-transplant outcomes, making it a valuable addition to renal transplant care.
  • In March 2025, Hansa Biopharma AB announced the completion of enrollment for its 20-HMedIdeS-19 Post Authorization Efficacy and Safety (PAES) study, an open-label, Phase 3 confirmatory trial in Europe. The study is evaluating one-year patient and graft survival in highly sensitized patients who have undergone HLA-incompatible kidney transplantation following desensitization treatment with imlifidase, aiming to further validate the therapy's clinical effectiveness and safety.
  • In February 2025, Eledon Pharmaceuticals, Inc. announced that its investigational anti-CD40L antibody, tegoprubart, was utilized as a key component of the immunosuppressive regimen in a groundbreaking xenotransplantation procedure. On January 25, 2025, a patient received a genetically modified pig kidney at Massachusetts General Hospital (MGH), with the transplant performed in collaboration with eGenesis, marking a significant milestone in the advancement of cross-species organ transplantation.

Key takeaways from the renal transplant therapeutics market report study

  • Market size analysis for current renal transplant therapeutics market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the renal transplant therapeutics market.
  • Various opportunities available for the other competitors in the renal transplant therapeutics market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current renal transplant therapeutics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for renal transplant therapeutics market growth in the coming future?

Target audience who can benefit from this renal transplant therapeutics market report study

  • Renal transplant therapeutics product providers
  • Research organizations and consulting companies
  • Renal transplant therapeutics-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in renal transplant therapeutics
  • Various end-users who want to know more about the renal transplant therapeutics market and the latest technological developments in the renal transplant therapeutics market.

Frequently Asked Questions for the Renal Transplant Therapeutics Market:

1. What are renal transplant therapeutics?

  • Renal transplant therapeutics are drugs used to support kidney transplant patients by preventing organ rejection and ensuring the long-term function of the transplanted kidney. These therapies primarily include immunosuppressive drugs, anti-infective agents, and supportive medications.

2. What is the market for renal transplant therapeutics?

  • The renal transplant therapeutics market was valued at USD 11,359.70 million in 2024, growing at a CAGR of 6.29% during the forecast period from 2025 to 2032 to reach USD 18,398.30 million by 2032.

3. What are the drivers for the renal transplant therapeutics market?

  • The demand for renal transplant therapeutics is increasing due to the growing number of kidney transplants worldwide and the rising prevalence of chronic kidney disease, renal failure, and end-stage renal disease (ESRD). These conditions often cause permanent kidney damage, leading to a greater need for transplants. Additionally, ongoing R&D efforts and new product launches by key players in transplant rejection drugs are supporting market growth. Together, these factors are expected to drive steady expansion of the renal transplant therapeutics market from 2025 to 2032.

4. Who are the key players operating in the renal transplant therapeutics market?

  • Some of the key market players operating in the renal transplant therapeutics market include Novartis AG, Sanofi, Astellas Pharma Inc., Asahi Kasei Corporation, F. Hoffmann-La Roche Ltd., Pfizer Inc., Bristol-Myers Squibb Company, GSK plc, Biogen, Zydus Group, Eledon Pharmaceuticals, Inc., AbbVie Inc., CSL, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., and others.

5. Which region has the highest share in the renal transplant therapeutics market?

  • North America is projected to hold the largest share of the renal transplant therapeutics market in 2024, driven by several key factors. This regional dominance is primarily attributed to the rising prevalence of kidney diseases such as CKD and ESRD, a growing number of kidney transplants, a well-established healthcare infrastructure, and ongoing product development by leading companies. Collectively, these factors are positioning North America as the leading market in the global renal transplant therapeutics market.

Table of Contents

1. Renal Transplant Therapeutics Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Renal Transplant Therapeutics Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Renal Transplant Therapeutics Market Key Factors Analysis

  • 5.1. Renal Transplant Therapeutics Market Drivers
    • 5.1.1. The growing number of kidney transplant performed globally
    • 5.1.2. The rising prevalence of chronic kidney disease, renal failure, end-stage renal disease (ESRD) and its associated risk factors
    • 5.1.3. Increasing R&D activities and product launches by key players in domain of transplant rejection drugs
  • 5.2. Renal Transplant Therapeutics Market Restraints and Challenges
    • 5.2.1. Long-term risk and potential adverse effects associated with kidney transplant drugs
    • 5.2.2. Stringent regulatory requirements for drug approvals
  • 5.3. Renal Transplant Therapeutics Market Opportunity
    • 5.3.1. Advances in Personalized immunosuppression and immunoengineering

6. Renal Transplant Therapeutics Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Renal Transplant Therapeutics Market Assessment

  • 7.1. By Drug Class
    • 7.1.1. Calcineurin Inhibitors
    • 7.1.2. Interleukin Inhibitors
    • 7.1.3. mTOR Inhibitors
    • 7.1.4. Inosine Monophosphate Dehydrogenase (IMPDH) Inhibitors
    • 7.1.5. Others
  • 7.2. By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Parenteral
  • 7.3. By Modality
    • 7.3.1. Small Molecule
    • 7.3.2. Biologics
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Renal Transplant Therapeutics Market Size in USD million (2022-2032)
      • 7.4.1.2. Canada Renal Transplant Therapeutics Market Size in USD million (2022-2032)
      • 7.4.1.3. Mexico Renal Transplant Therapeutics Market Size in USD million (2022-2032)
    • 7.4.2. Europe
      • 7.4.2.1. France Renal Transplant Therapeutics Market Size in USD million (2022-2032)
      • 7.4.2.2. Germany Renal Transplant Therapeutics Market Size in USD million (2022-2032)
      • 7.4.2.3. United Kingdom Renal Transplant Therapeutics Market Size in USD million (2022-2032)
      • 7.4.2.4. Italy Renal Transplant Therapeutics Market Size in USD million (2022-2032)
      • 7.4.2.5. Spain Renal Transplant Therapeutics Market Size in USD million (2022-2032)
      • 7.4.2.6. Rest of Europe Renal Transplant Therapeutics Market Size in USD million (2022-2032)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Renal Transplant Therapeutics Market Size in USD million (2022-2032)
      • 7.4.3.2. Japan Renal Transplant Therapeutics Market Size in USD million (2022-2032)
      • 7.4.3.3. India Renal Transplant Therapeutics Market Size in USD million (2022-2032)
      • 7.4.3.4. Australia Renal Transplant Therapeutics Market Size in USD million (2022-2032)
      • 7.4.3.5. South Korea Renal Transplant Therapeutics Market Size in USD million (2022-2032)
      • 7.4.3.6. Rest of Asia-Pacific Renal Transplant Therapeutics Market Size in USD million (2022-2032)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East Renal Transplant Therapeutics Market Size in USD million (2022-2032)
      • 7.4.4.2. Africa Renal Transplant Therapeutics Market Size in USD million (2022-2032)
      • 7.4.4.3. South America Renal Transplant Therapeutics Market Size In USD Million (2022-2032)

8. Renal Transplant Therapeutics Market Company and Product Profiles

  • 8.1. Novartis AG
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Sanofi
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Astellas Pharma Inc.
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Asahi Kasei Corporation
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. F. Hoffmann-La Roche Ltd.
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Pfizer Inc.
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Bristol-Myers Squibb Company
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. GSK plc
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Biogen
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. Zydus Group
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Eledon Pharmaceuticals, Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. AbbVie Inc.
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. CSL
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Teva Pharmaceutical Industries Ltd.
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. Johnson & Johnson Services, Inc.
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제